Abituzumab

Metastatic Colorectal Cancer

SFJ Pharmaceuticals X, LTD.monoclonal_antibodyPhase 2Dormant

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 65/ 100

Competitive context

840 Active assets in the Metastatic Colorectal Cancer cohort.

Asset / Sponsor	Phase	Rating
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
MARBLE DUST James Varani	Phase 2/3	BB
FLUOROURACILUM Washington University School of Medicine	Phase 4	BB
PANITUMUMAB M.D. Anderson Cancer Center	Phase 3	BB
Cetuximab Shanghai Henlius Biotech	Phase 4	BB

View all 50 →

Same molecule, other indications

Abituzumab is also rated in:

metastatic prostate carcinomaDormant

B

Indicative ·

57 / 100

Colorectal and Ovarian Cancer Patients With Liver MetastasesDormant

CC

Indicative ·

47 / 100

metastatic carcinoma in the boneDormant

CC

Indicative ·

46 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.